Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
RNAi-based drug design: considerations and future directions
More than 25 years after its discovery, the post-transcriptional gene regulation mechanism
termed RNAi is now transforming pharmaceutical development, proved by the recent FDA …
termed RNAi is now transforming pharmaceutical development, proved by the recent FDA …
Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery
CM Zimmermann, D Baldassi, K Chan… - Journal of Controlled …, 2022 - Elsevier
While all the siRNA drugs on the market target the liver, the lungs offer a variety of currently
undruggable targets which could potentially be treated with RNA therapeutics. Hence, local …
undruggable targets which could potentially be treated with RNA therapeutics. Hence, local …
Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection
The continuous evolution of SARS-CoV-2 variants complicates efforts to combat the ongoing
pandemic, underscoring the need for a dynamic platform for the rapid development of pan …
pandemic, underscoring the need for a dynamic platform for the rapid development of pan …
COVID-19 drug discovery and treatment options
Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused substantial morbidity and …
respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused substantial morbidity and …
Inhibition of SARS-CoV-2 replication in the lung with siRNA/VIPER polyplexes
SARS-CoV-2 has been the cause of a global pandemic since 2019 and remains a medical
urgency. siRNA-based therapies are a promising strategy to fight viral infections. By …
urgency. siRNA-based therapies are a promising strategy to fight viral infections. By …
XNAzymes targeting the SARS-CoV-2 genome inhibit viral infection
The unprecedented emergence and spread of SARS-CoV-2, the coronavirus responsible for
the COVID-19 pandemic, underscores the need for diagnostic and therapeutic technologies …
the COVID-19 pandemic, underscores the need for diagnostic and therapeutic technologies …
[HTML][HTML] Lab-scale siRNA and mRNA LNP manufacturing by various microfluidic mixing techniques–an evaluation of particle properties and efficiency
DC Jürgens, L Deßloch, D Porras-Gonzalez… - OpenNano, 2023 - Elsevier
Abstract Lipid Nanoparticles (LNPs) are promising drug delivery systems for various RNAs
such as small interfering (siRNA) and messenger RNA (mRNA). Microfluidic mixing is a …
such as small interfering (siRNA) and messenger RNA (mRNA). Microfluidic mixing is a …
Treatment of COVID‐19 patients with a SARS‐CoV‐2‐specific siRNA‐peptide dendrimer formulation
M Khaitov, A Nikonova, I Kofiadi, I Shilovskiy… - Allergy, 2023 - Wiley Online Library
Background Severe acute respiratory syndrome corona virus (SARS‐CoV‐2) infection
frequently causes severe and prolonged disease but only few specific treatments are …
frequently causes severe and prolonged disease but only few specific treatments are …
[HTML][HTML] Safety, efficacy, and relapse of nirmatrelvir-ritonavir in kidney transplant recipients infected with SARS-CoV-2
Introduction The efficacy of nirmatrelvir-ritonavir (NR; Paxlovid, Pfizer, New York, NY) to
decrease the risk of progression to severe COVID-19 in high-risk patients has been …
decrease the risk of progression to severe COVID-19 in high-risk patients has been …